Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

Inclusion Criteria: * Female and male patients aged between 18 and 75 years * Patients with renal transplant having a stable eGFR, who are in stable condition, 9 months after transplantation, irrespective of their diabetes status * Females of child bearing potential must be using adequate contraceptive precautions * Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit * Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form Exclusion Criteria: * Type 1 diabetes mellitus. * HbA1c \> 10% * Use of SGLT-2 inhibitor within the past 2 months * Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion. * eGFR \<25 ml/min/1.73m² (CKD-EPI Formula). * Uncontrolled arterial hypertension (RR \> 180/110 mmHg). * Congestive heart failure (CHF) NYHA stage IV. * Recurrent urinary tract infections (bacterial or fungal) * Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmacokinetics of the drug. * Significant laboratory abnormalities such as SGOT or SGPT levels more than 5 x above the upper limit of normal range. * Antihypertensives are allowed but should be kept stable throughout the study period. * Statins and other antihyperlipidemic drugs are allowed but should be kept stable throughout the study period. * Drug or alcohol abusus * Pregnant or breast-feeding patients * Patients with contraindications to MRI